购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 Species 筛选
  • E. coli
    (1)
  • Human
    (58)
  • Influenza B
    (4)
TargetMol | Tags 通过 Tag 筛选
  • C-His
    (3)
  • C-His-Avi
    (51)
  • N-6xHis
    (1)
  • N-GST
    (1)
  • N-His
    (5)
  • N-His-Avi
    (1)
  • N-mFc
    (1)
TargetMol | Tags 通过 Expression System 筛选
  • Baculovirus Insect Cells
    (1)
  • E. coli
    (21)
  • HEK293 Cells
    (41)
筛选
搜索结果
TargetMol产品目录中 "

k-ras4b

"的结果
  • 抑制剂&激动剂
    90
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    63
    TargetMol | Recombinant_Protein
  • 多肽产品
    2
    TargetMol | Peptide_Products
  • 染料试剂
    1
    TargetMol | Dye_Reagents
  • PROTAC
    7
    TargetMol | PROTAC
  • 天然产物
    10
    TargetMol | Natural_Products
TargetMolTargetMol对比
KRAS Protein, Human, Recombinant (G12S, GST)NS,C-K-RAS,K-RAS2A,KRAS1,K-RAS2B,KRAS2,K-RAS4A,CFC2,RALD,K-RAS,NS3,KI-RAS,Kirsten rat sarcoma viral oncogene homolog,RASK2,K-RAS4B
TMPU-00001
KRAS Protein, Human, Recombinant (G12S, GST) is expressed in E. coli expression system with GST tag. The accession number is P01116.
    5日内发货
    询价
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)K-RAS2A,K-RAS4B,KI-RAS,RALD,C-K-RAS,RASK2,NS,MHC,NS3,K-RAS4A,GTPase Kras,K-Ras 2,CFC2,KRAS1,K-RAS2B,KRAS,KRAS2
    TMPK-01507
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 12600
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)K-Ras 2,NS,NS3,K-RAS2B,CFC2,MHC,KRAS1,GTPase Kras,K-RAS4A,KRAS2,RASK2,K-RAS4B,RALD,C-K-RAS,KI-RAS,K-RAS2A,KRAS
    TMPK-01512
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)K-RAS2A,RALD,NS3,K-Ras 2,KI-RAS,NS,MHC,K-RAS2B,K-RAS4A,KRAS1,C-K-RAS,KRAS2,GTPase Kras,K-RAS4B,CFC2,RASK2,KRAS
    TMPK-01430
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 4200
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)KRAS1,MHC,K-RAS2B,K-RAS4B,NS,GTPase Kras,K-Ras 2,KI-RAS,K-RAS4A,KRAS2,RALD,C-K-RAS,K-RAS2A,RASK2,CFC2,KRAS,NS3
    TMPK-01528
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)RASK2,K-RAS4A,K-RAS4B,KRAS2,CFC2,MHC,KRAS,KI-RAS,K-RAS2B,C-K-RAS,NS3,GTPase Kras,K-RAS2A,KRAS1,K-Ras 2,NS,RALD
    TMPK-01432
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 12600
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-LabeledKRAS2,NS3,RASK2,KI-RAS,RALD,K-RAS2B,K-RAS4B,GTPase Kras,C-K-RAS,K-RAS2A,KRAS1,KRAS,K-Ras 2,CFC2,MHC,K-RAS4A,NS
    TMPK-01435
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 18900
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-LabeledRASK2,KRAS2,KRAS1,MHC,C-K-RAS,KI-RAS,K-RAS4B,RALD,K-RAS4A,NS3,KRAS,NS,GTPase Kras,K-Ras 2,K-RAS2A,CFC2,K-RAS2B
    TMPK-01438
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 18900
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-LabeledRASK2,KI-RAS,C-K-RAS,KRAS,MHC,NS,K-RAS4A,K-RAS2B,CFC2,K-Ras 2,K-RAS2A,KRAS1,GTPase Kras,KRAS2,NS3,K-RAS4B,RALD
    TMPK-01440
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 18900
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B,KI-RAS,K-Ras 2,RASK2,KRAS,K-RAS4A,K-RAS4B,GTPase Kras,RALD,CFC2,NS3
    TMPK-01456
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 12600
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), BiotinylatedKRAS1,NS,CFC2,K-RAS4B,RASK2,K-Ras 2,KI-RAS,GTPase Kras,KRAS,NS3,RALD,C-K-RAS,KRAS2,MHC,K-RAS2B,K-RAS4A,K-RAS2A
    TMPK-01402
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 6300
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)NS3,K-RAS2A,CFC2,KRAS,GTPase Kras,K-RAS2B,K-Ras 2,KI-RAS,C-K-RAS,KRAS2,RALD,RASK2,K-RAS4A,K-RAS4B,MHC,NS,KRAS1
    TMPK-01465
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), BiotinylatedNS3,KRAS1,K-Ras 2,K-RAS2A,K-RAS2B,C-K-RAS,K-RAS4A,CFC2,KRAS2,KRAS,GTPase Kras,RALD,KI-RAS,NS,MHC,K-RAS4B,RASK2
    TMPK-01479
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 5670
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), BiotinylatedCFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3,GTPase Kras,KRAS2,K-RAS4B,K-RAS2A,KI-RAS,KRAS,NS,RASK2,K-RAS4A,KRAS1,K-RAS2B
    TMPK-01525
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 5670
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), BiotinylatedC-K-RAS,K-RAS4B,GTPase Kras,K-RAS4A,K-RAS2A,KRAS2,CFC2,RASK2,NS,K-Ras 2,KRAS,MHC,NS3,K-RAS2B,RALD,KRAS1,KI-RAS
    TMPK-01427
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 6300
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)RASK2,CFC2,GTPase Kras,KRAS,K-RAS2B,MHC,K-RAS2A,K-RAS4A,KRAS2,KRAS1,NS,KI-RAS,C-K-RAS,K-RAS4B,RALD,K-Ras 2,NS3
    TMPK-01434
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 12600
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)C-K-RAS,KRAS,RASK2,K-Ras 2,K-RAS2A,MHC,CFC2,K-RAS4B,K-RAS2B,RALD,NS3,GTPase Kras,KRAS1,KRAS2,K-RAS4A,NS,KI-RAS
    TMPK-01461
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), BiotinylatedK-RAS2A,NS3,KRAS2,CFC2,K-RAS4B,GTPase Kras,RALD,MHC,KRAS,RASK2,K-Ras 2,KI-RAS,NS,K-RAS4A,C-K-RAS,KRAS1,K-RAS2B
    TMPK-01399
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 6300
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), BiotinylatedNS,KRAS,KRAS1,KRAS2,MHC,RALD,K-RAS4A,K-RAS2A,K-RAS4B,K-RAS2B,KI-RAS,RASK2,CFC2,GTPase Kras,K-Ras 2,C-K-RAS,NS3
    TMPK-01404
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 6300
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)K-Ras 2,KI-RAS,CFC2,KRAS1,GTPase Kras,KRAS,K-RAS4B,RALD,NS3,K-RAS4A,RASK2,NS,MHC,K-RAS2A,K-RAS2B,C-K-RAS,KRAS2
    TMPK-01403
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 4200
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    KRAS Protein,Human,Recombinant(G12C & Q61H, His)NS,CFC2,K-RAS4B,C-K-RAS,KRAS2,K-RAS2B,K-RAS,Kirsten rat sarcoma viral oncogene homolog,K-RAS2A,KI-RAS,NS3,K-RAS4A,KRAS1,RASK2,RALD
    TMPY-04116
    KRAS Protein,Human,Recombinant(G12C & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2.
    • ¥ 3820
    现货
    规格
    数量
    TargetMolTargetMol对比
    KRAS Protein, Human, Recombinant (61Q, His)Kirsten rat sarcoma viral oncogene homolog,K-RAS2B,NS3,K-RAS4B,RALD,K-RAS2A,KI-RAS,KRAS1,KRAS2,K-RAS,NS,K-RAS4A,CFC2,RASK2,C-K-RAS
    TMPY-06138
    KRAS Protein, Human, Recombinant (61Q, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 21.9 kDa and the accession number is P01116-2.
    • ¥ 3820
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)K-RAS2A,GTPase Kras,K-Ras 2,RALD,KRAS2,K-RAS4A,MHC,K-RAS4B,CFC2,KRAS,KI-RAS,NS,NS3,C-K-RAS,KRAS1,RASK2,K-RAS2B
    TMPK-01490
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), BiotinylatedNS3,MHC,KRAS,RALD,CFC2,K-RAS2B,GTPase Kras,K-Ras 2,K-RAS2A,KRAS1,K-RAS4A,C-K-RAS,RASK2,K-RAS4B,NS,KI-RAS,KRAS2
    TMPK-01536
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 5670
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi), BiotinylatedK-RAS4A,NS,C-K-RAS,RALD,GTPase Kras,K-RAS2A,K-RAS4B,CFC2,RASK2,MHC,KI-RAS,K-Ras 2,NS3,KRAS,KRAS1,KRAS2,K-RAS2B
    TMPK-01537
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 5670
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), BiotinylatedKRAS2,RALD,C-K-RAS,NS3,MHC,CFC2,KRAS,KI-RAS,K-RAS4B,NS,K-RAS2A,KRAS1,RASK2,GTPase Kras,K-Ras 2,K-RAS2B,K-RAS4A
    TMPK-01407
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 6300
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi)RALD,C-K-RAS,MHC,K-RAS2A,GTPase Kras,KRAS,NS,RASK2,K-RAS4B,K-RAS4A,KRAS1,K-RAS2B,KRAS2,K-Ras 2,NS3,CFC2,KI-RAS
    TMPK-01431
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 12600
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-LabeledKRAS,GTPase Kras,K-RAS2A,K-RAS4A,NS,CFC2,RALD,MHC,C-K-RAS,NS3,RASK2,K-Ras 2,K-RAS4B,KRAS1,KRAS2,K-RAS2B,KI-RAS
    TMPK-01439
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 18900
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), BiotinylatedRASK2,CFC2,K-Ras 2,NS3,GTPase Kras,KRAS1,K-RAS4B,K-RAS2B,MHC,KI-RAS,NS,K-RAS2A,KRAS2,KRAS,C-K-RAS,K-RAS4A,RALD
    TMPK-01453
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 5670
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi), BiotinylatedK-Ras 2,CFC2,RALD,MHC,KRAS,K-RAS4B,NS3,C-K-RAS,NS,KI-RAS,K-RAS2B,K-RAS4A,GTPase Kras,KRAS1,RASK2,KRAS2,K-RAS2A
    TMPK-01457
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 5670
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)K-RAS2A,NS3,KRAS1,KRAS2,MHC,NS,K-RAS2B,K-RAS4A,KRAS,CFC2,RASK2,KI-RAS,RALD,GTPase Kras,K-Ras 2,K-RAS4B,C-K-RAS
    TMPK-01489
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 12600
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)KRAS,NS3,GTPase Kras,RASK2,K-RAS2B,C-K-RAS,MHC,KRAS2,KI-RAS,KRAS1,K-Ras 2,NS,K-RAS4A,RALD,CFC2,K-RAS2A,K-RAS4B
    TMPK-01526
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 12600
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), BiotinylatedNS,KRAS1,RALD,K-RAS2A,K-RAS2B,K-RAS4A,MHC,RASK2,KRAS,GTPase Kras,KRAS2,CFC2,C-K-RAS,NS3,K-Ras 2,KI-RAS,K-RAS4B
    TMPK-01400
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 6300
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), BiotinylatedC-K-RAS,K-RAS4A,GTPase Kras,K-RAS2A,NS,K-RAS2B,MHC,KRAS2,K-RAS4B,KI-RAS,NS3,KRAS,K-Ras 2,RALD,CFC2,RASK2,KRAS1
    TMPK-01464
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 5670
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-LabeledCFC2,KRAS,K-RAS4B,MHC,K-RAS2B,KRAS1,NS3,K-RAS2A,NS,K-RAS4A,RASK2,RALD,KRAS2,GTPase Kras,C-K-RAS,KI-RAS,K-Ras 2
    TMPK-01471
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 5670
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    KRAS Protein,Human,Recombinant(G12D & Q61H, His)Kirsten rat sarcoma viral oncogene homolog,KRAS2,KI-RAS,RASK2,CFC2,K-RAS4A,K-RAS2B,NS3,KRAS1,RALD,K-RAS,C-K-RAS,K-RAS2A,K-RAS4B,NS
    TMPY-04113
    KRAS Protein,Human,Recombinant(G12D & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2.
    • ¥ 3820
    现货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)NS,NS3,KRAS2,RASK2,MHC,RALD,K-Ras 2,K-RAS4B,C-K-RAS,KI-RAS,K-RAS4A,K-RAS2B,K-RAS2A,GTPase Kras,KRAS,CFC2,KRAS1
    TMPK-01510
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 12600
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)MHC,NS,KRAS1,K-RAS2A,GTPase Kras,KRAS,RALD,KRAS2,RASK2,C-K-RAS,KI-RAS,K-Ras 2,K-RAS4B,CFC2,K-RAS4A,NS3,K-RAS2B
    TMPK-01518
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 12600
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)K-RAS4A,MHC,GTPase Kras,K-Ras 2,KRAS2,K-RAS2B,CFC2,RASK2,RALD,K-RAS4B,NS,NS3,KRAS,C-K-RAS,KRAS1,K-RAS2A,KI-RAS
    TMPK-01488
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)K-RAS4A,KRAS1,MHC,K-RAS2B,CFC2,GTPase Kras,K-RAS4B,KRAS2,NS3,K-RAS2A,NS,K-Ras 2,KRAS,C-K-RAS,KI-RAS,RALD,RASK2
    TMPK-01529
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), BiotinylatedRALD,KRAS1,KRAS2,K-RAS2B,CFC2,NS3,GTPase Kras,MHC,K-RAS2A,KI-RAS,C-K-RAS,K-Ras 2,K-RAS4A,KRAS,NS,K-RAS4B,RASK2
    TMPK-01408
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 6300
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)GTPase Kras,NS3,K-Ras 2,K-RAS2B,RALD,MHC,RASK2,K-RAS4A,CFC2,KRAS2,KRAS,K-RAS4B,KRAS1,C-K-RAS,KI-RAS,K-RAS2A,NS
    TMPK-01433
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 12600
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,CFC2,K-RAS4B,K-RAS2A,RALD,KRAS2,K-RAS2B,C-K-RAS,GTPase Kras
    TMPK-01451
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)K-Ras 2,GTPase Kras,KRAS2,MHC,K-RAS4A,CFC2,K-RAS2A,KRAS1,RASK2,NS,RALD,KI-RAS,K-RAS4B,KRAS,NS3,K-RAS2B,C-K-RAS
    TMPK-01458
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)C-K-RAS,KI-RAS,KRAS1,K-RAS4A,KRAS2,CFC2,MHC,NS3,K-RAS2B,NS,K-RAS4B,K-Ras 2,K-RAS2A,RASK2,KRAS,GTPase Kras,RALD
    TMPK-01463
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)NS,RALD,C-K-RAS,RASK2,K-RAS2B,KRAS2,KRAS,K-RAS2A,K-RAS4A,KRAS1,MHC,K-Ras 2,K-RAS4B,GTPase Kras,KI-RAS,NS3,CFC2
    TMPK-01527
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 3780
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)MHC,CFC2,K-Ras 2,RALD,K-RAS4A,NS,RASK2,GTPase Kras,K-RAS2B,K-RAS4B,KRAS2,KRAS,KI-RAS,NS3,K-RAS2A,C-K-RAS,KRAS1
    TMPK-01401
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    • ¥ 4200
    5日内发货
    规格
    数量
    TargetMolTargetMol对比
    HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), BiotinylatedMHC,K-Ras 2,NS,K-RAS4A,KRAS,NS3,KI-RAS,K-RAS2A,K-RAS2B,RALD,C-K-RAS,RASK2,CFC2,KRAS2,K-RAS4B,KRAS1,GTPase Kras
    TMPK-01429
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    • ¥ 6300
    5日内发货
    规格
    数量